drugset / Trial / NCT02817945
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
NaSingle-groupOpen-labelDiagnostic
Summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluate the efficacy of 68Ga-NOTA-3PTATE-RGD in lung cancer patients and neuroendocrine neoplam patients. A single dose of 111-185 Mega-Becquerel (MBq) 68Ga-NOTA-3P-TATE-RGD will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.
Timeline
- Start
- 2016-06-01
- Primary completion
- 2020-12-01
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-NOTA-3P-TATE-RGD | Peptide | 111 mbq | Intravenous |
| Subject | 68Ga-NOTA-3P-TATE-RGD | Peptide | 185 mbq | Intravenous |